Featured Research

from universities, journals, and other organizations

Breakthrough New Therapy Uses Antibody-Targeted Chemotherapy To Fight Leukemia

Date:
May 19, 1999
Source:
Fred Hutchinson Cancer Research Center
Summary:
Scientists presented promising data today at the 35th Annual Meeting of the American Society of Clinical Oncology (ASCO) on the use of a pioneering drug technology known as "antibody-targeted chemotherapy" to fight acute myelogenous leukemia (AML) - a virulent and often fatal form of cancer. The experimental agent, CMA-676, induces remission in a significant proportion of patients with few serious side effects.

Scientists presented promising data today at the 35th Annual Meeting of the American Society of Clinical Oncology (ASCO) on the use of a pioneering drug technology known as "antibody-targeted chemotherapy" to fight acute myelogenous leukemia (AML) - a virulent and often fatal form of cancer. The experimental agent, CMA-676, induces remission in a significant proportion of patients with few serious side effects. CMA-676 represents the first successful application of antibody-targeted chemotherapy.

AML is an aggressive, life-threatening disease in which certain white blood cells become cancerous and rapidly replace normal bone marrow and blood cells. AML is among the most serious forms of adult leukemia, with a relatively high fatality rate. Most patients require intensive chemotherapy to achieve complete remission, and some also must undergo bone marrow transplants. Up to half of patients with AML, even after such intensive treatment, have residual leukemic cells or experience a relapse.

Because current chemotherapy drugs to treat AML are non-specific - destroying good as well as bad cells - patients receiving standard chemotherapy tend to become very sick. Researchers at the Fred Hutchinson Cancer Research Center, in collaboration with scientists from thirteen leading leukemia centers, including University of Chicago Medical Center, MD Anderson Cancer Center, and the University of Pennsylvania Cancer Center, are working with Wyeth-Ayerst Research and Celltech PLC to study CMA-676, an antibody-drug conjugate that delivers treatment directly to the leukemia cells.

The specificity of the conjugate lies in the antibody, which recognizes a cell-surface molecule that is abundant on AML cells. Importantly, however, the cell surface molecule is absent from normal blood stem cells, the seeds from which normal blood and immune cells originate. Specially engineered to carry a novel and extremely potent chemotherapy agent known as calicheamicin, the antibody selectively targets leukemic blast cells, while sparing cells that are responsible for replenishing normal blood cells once the leukemia is eradicated.

Promising results continue to emerge from a pivotal Phase II trial in the U.S., which involves patients who experienced a relapse following initial AML chemotherapy. CMA-676 given alone appears to produce remission among 36 percent of patients- a rate comparable to that of standard combination chemotherapy regimens. The data also indicate that CMA-676 has several important advantages over standard agents.

"The side effects are mild and well-tolerated relative to standard chemotherapy, especially by elderly patients," says Eric Sievers, M.D., of Fred Hutchinson Cancer Research Center. "Also, the treatment did not produce some of the more common chemotherapy-induced side effects."

Whereas standard combination chemotherapy treatment often produces significant major organ damage, and sores both in the mouth and in the intestinal tract (frequent sources for opportunistic infections), CMA-676 treatment does not. CMA-676 also is associated with a relatively low treatment-related mortality. As with standard chemotherapy treatments, CMA-676 produces a temporary suppression of bone marrow and blood cell counts.

CMA-676 is administered in two IV infusions fourteen days apart, and many patients have received the drug on an outpatient basis. Unlike standard chemotherapy regimens, which involve multiple drugs, CMA-676 is given alone. It is thus less likely to produce serious drug-drug interactions.

Similar studies of this new therapy are underway throughout Europe and Canada, and the developers of CMA-676 eventually hope to adapt their groundbreaking technology for the treatment of other devastating cancers.

###The Fred Hutchinson Cancer Research Center is an independent, non-profit research institution dedicated to the development and advancement of biomedical technology to eliminate cancer and other potentially fatal diseases. Recognized internationally for its pioneering work in bone marrow transplantation, the Center has four scientific divisions collaborating to form a unique environment for conducting basic and applied science. One of 35 National Cancer Institute-designated comprehensive cancer centers in the country, it is the only one in the Northwest. Visit the Hutchinson Center web site for more information at http://www.fhcrc.org.


Story Source:

The above story is based on materials provided by Fred Hutchinson Cancer Research Center. Note: Materials may be edited for content and length.


Cite This Page:

Fred Hutchinson Cancer Research Center. "Breakthrough New Therapy Uses Antibody-Targeted Chemotherapy To Fight Leukemia." ScienceDaily. ScienceDaily, 19 May 1999. <www.sciencedaily.com/releases/1999/05/990519065323.htm>.
Fred Hutchinson Cancer Research Center. (1999, May 19). Breakthrough New Therapy Uses Antibody-Targeted Chemotherapy To Fight Leukemia. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/1999/05/990519065323.htm
Fred Hutchinson Cancer Research Center. "Breakthrough New Therapy Uses Antibody-Targeted Chemotherapy To Fight Leukemia." ScienceDaily. www.sciencedaily.com/releases/1999/05/990519065323.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins